Therefore, novel therapeutic target responding to TLR pathogens from Gram-positive bacteria and viruses, affecting redundant SIRS pathways other than MD-2 or TLR4, is required in the alternative treatment of sepsis patients. The gene discussed is LY96; the disease is Sepsis.